Vaxart (OTCMKTS:VXRT) Shares Cross Below 200 Day Moving Average – What’s Next?

Vaxart, Inc. (OTCMKTS:VXRT)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.61 and traded as low as $0.58. Vaxart shares last traded at $0.61, with a volume of 200,011 shares traded.

Vaxart Stock Up 5.3%

The company’s fifty day moving average price is $0.64 and its 200 day moving average price is $0.61. The company has a market capitalization of $155.42 million, a P/E ratio of 4.27 and a beta of 1.09.

Vaxart (OTCMKTS:VXRT) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. Vaxart had a return on equity of 61.43% and a net margin of 14.51%.The business had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VXRT. Creative Planning bought a new stake in Vaxart during the second quarter worth about $33,000. Goldman Sachs Group Inc. acquired a new stake in Vaxart during the first quarter worth about $31,000. Invesco Ltd. increased its holdings in Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 70,568 shares during the period. Raymond James Financial Inc. increased its holdings in Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 34,075 shares during the period. Finally, Jones Financial Companies Lllp raised its position in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares in the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.